My Pitch: "http://barchart.com/charts/stocks/MNTA 17.47 0.28 (+1.63%)Thur, Sep 15th, 2011 NEWS@VOL ALERT CHART Development of novel drugs and the discovery of new biological processes."

My Pitch: "Cash = $6.33 per share; through Shire's acquisition of Baxter, solely own P3-proven Humira FOB; 20 mg Copaxone copy is only approved sole generic since Q4 2015; they await approval of more popular 40 mg version in 2H 2017. M281, now in P1 is superlative agonist for circulating fcn ABs."

My Pitch: "Love"

My Pitch: "Mnta
Abx
Abt
Fmi
Ssys
Tkmr
Enta
Ssh



"

My Pitch: "MNTA Copaxone approval could come any day,
adds interest to the dog days of summer!"

My Pitch: "high cash/share, generic lovenox risk mostly baked in in mid teens, multiple catalysts for upside via generic copaxone approval, patent infringement vs teva/watson/amphastar litigation, baxter backing for fob, low pe"

My Pitch: "Biosimilars"

My Pitch: "Their technology is what solved the heparin contamination problem. They know better than the primary manufacturer what is in the "soup"."